Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized phase II trial of Avastin [bevacizumab] plus gemcitabine plus 5FU [fluorouracil]/folinic acid (A + FFG) vs. Avastin plus oxaliplatin + 5FU/folinic acid (A + FOLFOX4) as therapy for patients with metastatic colorectal cancer

X
Trial Profile

A multicenter, randomized phase II trial of Avastin [bevacizumab] plus gemcitabine plus 5FU [fluorouracil]/folinic acid (A + FFG) vs. Avastin plus oxaliplatin + 5FU/folinic acid (A + FOLFOX4) as therapy for patients with metastatic colorectal cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 29 May 2009 Results presented at ASCO 2009.
    • 06 Jun 2007 Status changed from in progress to completed.
    • 28 Jul 2006 Status changed from recruiting to in progress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top